NCT01819740UnknownNot Applicable
Analysis of a New Biomarker for Prostate Cancer Diagnosis
Corporacion Parc Tauli1 site in 1 country28 target enrollmentStarted: April 2013Last updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Sponsor
- Enrollment
- 28
- Locations
- 1
- Primary Endpoint
- substance "HEM" concentration in seminal plasma (mEq/L measured by spectro-photometry
Study Overview
Brief Summary
The aim of our study is to determine if the levels of the "HEM" substance in seminal plasma are associated with the presence of prostate cancer in transrectal prostate biopsy.
Study Design
- Study Type
- Observational
- Observational Model
- Case Only
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 45 Years to 75 Years (Adult, Older Adult)
- Sex
- Male
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Clinical or laboratory suspected of prostate cancer
Exclusion Criteria
- •Inability to ejaculate
Outcomes
Primary Outcomes
substance "HEM" concentration in seminal plasma (mEq/L measured by spectro-photometry
Time Frame: 1 hour
Secondary Outcomes
No secondary outcomes reported
Investigators
MIRIAM BARRIO MUÑOZ
UROLOGY RESIDENT
Hospital de Sabadell
Study Sites (1)
Loading locations...
Similar Trials
Recruiting
Not Applicable
To Identify Potential New Urine Markers for the Screening of Prostate CancerProstate CancerNCT03914391Chinese University of Hong Kong10,000
Recruiting
Not Applicable
Predictive and Prognostic Markers for Treatment Outcomes in Prostate Cancer PatientsProstate CancerNCT03237026National Taiwan University Hospital360
Withdrawn
Not Applicable
Investigation of Protein Biomarkers of Prostate CancerProstate CancerNCT00323180University of New Mexico
Terminated
Not Applicable
Prostate Cancer Diagnosis Through NMR Spectroscopy of Semen and Prostatic SecretionsProstate CancerNCT00250757New Mexico Cancer Care Alliance101
Withdrawn
Not Applicable
Investigation of Urinary Biomarkers for the Detection of Prostate CancerUrineLiquid BiopsyProstate CancerNCT05454371Novosanis NV